Iodine intake as a risk factor for thyroid cancer: A comprehensive review of animal and human studies

Thyroid Research

Volumn 8, Issue 1, 2015, Pages

  Zimmermann, Michael B ^a   Galetti, Valeria ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Goiter; Iodine deficiency; Iodine excess; Iodine status; Iodine supplement; Iodized salt; Nodule; Thyroid cancer; Urinary iodine

Indexed keywords

THYROTROPIN;

ARTICLE; AUTOPSY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CELL PROLIFERATION; ELECTROLYTE INTAKE; HISTOLOGY; HUMAN; IODINE DEFICIENCY; IODINE INTAKE; NONHUMAN; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; SEA FOOD; THYROID CANCER;

EID: 84938550423     PISSN: None     EISSN: 17566614     Source Type: Journal    
DOI: 10.1186/s13044-015-0020-8     Document Type: Article

References (176)

1. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187-95.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-21.
3. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115:3801-7.
4. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-91.
5. Morris LGT, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23:886-92.
6. Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid. 2014;24:472-9.
7. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic" - screening and overdiagnosis. N Engl J Med. 2014;371:1765-7.
8. Bard D, Verger P, Hubert P. Chernobyl, 10 years after: health consequences. Epidemiol Rev. 1997;19:187-204.
9. Mazonakis M, Tzedakis A, Damilakis J, Gourtsoyiannis N. Thyroid dose from common head and neck CT examinations in children: is there an excess risk for thyroid cancer induction? Eur Radiol. 2007;17:1352-7.
10. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 1997;15:1263-73.
11. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569-78.
12. Rinaldi S, Lise M, Clavel-Chapelon F, Boutron-Ruault MC, Guillas G, Overvad K, et al. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer. 2012;131:E1004-14.
13. Hallgren S, Darnerud PO. Polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs) and chlorinated paraffins (CPs) in rats - testing interactions and mechanisms for thyroid hormone effects. Toxicology. 2002;177:227-43.
14. Zhang Y, Guo GL, Han X, Zhu C, Kilfoy BA, Zhu Y, et al. Do Polybrominated Diphenyl Ethers (PBDEs) Increase the Risk of Thyroid Cancer? Biosci Hypotheses. 2008;1:195-9.
15. Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control. 1999;10:583-95.
16. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol. 2015;3:286-95.
17. Wegelin C. Malignant disease of the thyroid gland and its relation to goiter in man and animals. Cancer Rev. 1928;3:297.
18. Global Iodine Nutrition Scorecard 2014. Available at: http://www.ign.org/cm-data/Scorecard-IGN-website-02-03-2015.pdf. Accessed 2 Mar 2015.
19. Carle A, Krejbjerg A, Laurberg P. Epidemiology of nodular goitre. Influence of iodine intake. Best Pract Res Clin Endocrinol Metab. 2014;28:465-79.
20. Cole WH, Majarakis JD, Slaughter DP. Incidence of carcinoma of the thyroid in nodular goiter. J Clin Endocrinol Metab. 1949;9:1007-11.
21. Feldt-Rasmussen U. Iodine and cancer. Thyroid. 2001;11:483-6.
22. Williams ED. Dietary iodide and thyroid cancer. In: Hall R, Köbberling J, editors. Thyroid disorders associated with iodine deficiency and excess. New York: Raven; 1985.
23. World Health Organization, United Nations Children's Fund, International Council for the Control of Iodine Deficiency Disorders. Assessment of iodine deficiency disorders and monitoring their elimination. A guide for programme managers. 3rd ed. Geneva: World Health Organization; 2007.
24. Zimmermann MB, Andersson M. Assessment of iodine nutrition in populations: past, present, and future. Nutr Rev. 2012;70:553-70.
25. Axelrad AA, Leblond CP. Induction of thyroid tumors in rats by a low iodine diet. Cancer. 1955;8:339-67.
26. Isler H, Leblond CP, Axelrad AA. Influence of age and of iodine intake on the production of thyroid tumors in the rat. J Natl Cancer Inst. 1958;21:1065-81.
27. Isler H. Effect of iodine on thyroid tumors induced in the rat by a low-iodine diet. J Natl Cancer Inst. 1959;23:675-93.
28. Schaller Jr RT, Stevenson JK. Development of carcinoma of the thyroid in iodine-deficient mice. Cancer. 1966;19:1063-80.
29. Fortner JG, George PA, Sternberg SS. The development of thyroid cancer and other abnormalities in Syrian hamsters maintained on an iodine deficient diet. Surg Forum. 1958;9:646-50.
30. Correa P, Welsh RA. The effect of excessive iodine intake on the thyroid gland of the rat. Arch Pathol. 1960;70:247-51.
31. Ohshima M, Ward JM. Promotion of N-Methyl-N-Nitrosourea-Induced Thyroid-Tumors by Iodine Deficiency in F344 Ncr Rats. J Natl Cancer I. 1984;73:289-96.
32. Ohshima M, Ward JM. Dietary iodine deficiency as a tumor promoter and carcinogen in male F344/Ncr rats. Cancer Res. 1986;46:877-83.
33. Kanno J, Onodera H, Furuta K, Maekawa A, Kasuga T, Hayashi Y. Tumor-promoting effects of both iodine deficiency and iodine excess in the rat-thyroid. Toxicol Pathol. 1992;20:226-35.
34. Yamashita H, Noguchi S, Murakami N, Kato R, Adachi M, Inoue S, et al. Effects of dietary iodine on chemical induction of thyroid-carcinoma. Acta Pathol Japon. 1990;40:705-12.
35. Cho YM, Imai T, Hasumura M, Hirose M. Lack of enhancement of susceptibility to mammary and thyroid carcinogenesis in rats exposed to DMBA and DHPN following prepubertal iodine deficiency. Cancer Sci. 2006;97:1031-6.
36. Boltze C, Brabant G, Dralle H, Gerlach R, Roessner A, Hoang-Vu C. Radiation-induced thyroid carcinogenesis as a function of time and dietary iodine supply: An in vivo model of tumorigenesis in the rat. Endocrinology. 2002;143:2584-92.
37. al-Saadi AA, Beierwaltes WH. Chromosomal changes in rat thyroid cells during iodine depletion and repletion. Cancer Res. 1966;26:676-88.
38. Riesco G, Taurog A, Larsen R, Krulich L. Acute and chronic responses to iodine deficiency in rats. Endocrinology. 1977;100:303-13.
39. Hill RN, Erdreich LS, Paynter OE, Roberts PA, Rosenthal SL, Wilkinson CF. Thyroid follicular cell carcinogenesis. Fundam Appl Toxicol. 1989;12:629-97.
40. Ward JM, Ohshima M. The role of iodine in carcinogenesis. Adv Exp Med Biol. 1986;206:529-42.
41. Kaplan MM. Progress in Thyroid-Cancer. Endocrin Metab Clin. 1990;19:469-78.
42. Doniach I, Williams ED. The development of thyroid and pituitary tumours in the rat two years after partial thyroidectomy. Br J Cancer. 1962;16:222-31.
43. Purves HD, Griesbach WE. Studies on experimental goitre; thyroid tumours in rats treated with thiourea. Br J Exp Pathol. 1947;28:46-53.
44. Wynford-Thomas D, Stringer BMJ, Williams ED. Desensitization of rat-thyroid to the growth-stimulating action of Tsh during prolonged goitrogen administration - persistence of refractoriness following withdrawal of stimulation. Acta Endocrinol (Copenh). 1982;101:562-9.
45. Uyttersprot N, Pelgrims N, Carrasco N, Gervy C, Maenhaut C, Dumont JE, et al. Moderate doses of iodide in vivo inhibit cell proliferation and the expression of thyroperoxidase and Na+/I- symporter mRNAs in dog thyroid. Mol Cell Endocrinol. 1997;131:195-203.
46. Eng PHK, Cardona GR, Fang SL, Previti M, Alex S, Carrasco N, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999;140:3404-10.
47. Krohn K, Maier J, Paschke R. Mechanisms of Disease: hydrogen peroxide, DNA damage and mutagenesis in the development of thyroid tumors. Nat Clin Pract Endoc. 2007;3:713-20.
48. Maier J, van Steeg H, van Oostrom C, Paschke R, Weiss RE, Krohn K. Iodine deficiency activates antioxidant genes and causes DNA damage in the thyroid gland of rats and mice. Biochim Biophys Acta. 2007;1773:990-9.
49. Vitale M, Di Matola T, D'Ascoli F, Salzano S, Bogazzi F, Fenzi G, et al. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology. 2000;141:598-605.
50. Cardoso LC, Martins DC, Figueiredo MD, Rosenthal D, Vaisman M, Violante AH, et al. Ca(2+)/nicotinamide adenine dinucleotide phosphate-dependent H(2)O(2) generation is inhibited by iodide in human thyroids. J Clin Endocrinol Metab. 2001;86:4339-43.
51. Langer R, Burzler C, Bechtner G, Gartner R. Influence of iodide and iodolactones on thyroid apoptosis. Evidence that apoptosis induced by iodide is mediated by iodolactones in intact porcine thyroid follicles. Exp Clin Endocr Diab. 2003;111:325-9.
52. Gartner R, Rank P, Ander B. The role of iodine and delta-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells. Hormones (Athens). 2010;9:60-6.
53. Kimura ET, Nikiforova MN, Zhu ZW, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-7.
54. Liu XH, Chen GG, Vlantis AC, van Hasselt CA. Iodine mediated mechanisms and thyroid carcinoma. Crit Rev Cl Lab Sci. 2009;46:302-18.
55. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 2008;15:191-205.
56. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1612-7.
57. Fuziwara CS, Kimura ET. High iodine blocks a Notch/miR-19 loop activated by the BRAF(V600E) oncoprotein and restores the response to TGFbeta in thyroid follicular cells. Thyroid. 2014;24:453-62.
58. Shi YF, Zou MJ, Schmidt H, Juhasz F, Stensky V, Robb D, et al. High-rates of Ras Codon-61 mutation in thyroid-tumors in an iodide-deficient area. Cancer Res. 1991;51:2690-3.
59. Fiore AP, Fuziwara CS, Kimura ET. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells. Thyroid. 2009;19:1249-56.
60. Xiang J, Wang XM, Wang ZY, Wu Y, Li DS, Shen Q, et al. Effect of different iodine concentrations on well-differentiated thyroid cancer cell behavior and its inner mechanism. Cell Biochem Biophys. 2015;71:299-305.
61. Langsteger W, Koltringer P, Wolf G, Dominik K, Buchinger W, Binter G, et al. The impact of geographical, clinical, dietary and radiation-induced features in epidemiology of thyroid cancer. Eur J Cancer. 1993;29A:1547-53.
62. Saxen E, Franssila K, Bjarnason O, Normann T, Ringertz N. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand A. 1978;86A:483-6.
63. Hedinger CE, Sobin LH. Histological Typing of Thyroid Tumours. Geneva: World Health Organization (International Histological Classification of Tumours, No 11); 1974.
64. Verkooijen HM, Fioretta G, Pache JC, Franceschi S, Raymond L, Schubert H, et al. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes Control. 2003;14:13-7.
65. Walthard B. Der Gestaltwandel Der Struma Maligna Mit Bezug Auf Die Jodprophylaxe Des Kropfes. Schweiz Med Wochenschr. 1963;93:809.
66. Hofstadter F. Frequency and morphology of malignant-tumors of the thyroid before and after the introduction of iodine-prophylaxis. Virchows Arch A Pathol Anat Histol. 1980;385:263-70.
67. Bubenhofer R, Hedinger C. [Thyroid neoplasms before and after the prophylactic supplementation of table salt with iodine]. Schweiz Med Wochenschr. 1977;107:733-41.
68. Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Marechaud R, Niccoli-Sire P, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150:133-9.
69. CI5plus: Cancer Incidence In Five Continents Time Trends. Available at: http://ci5.iarc.fr/CI5plus/Pages/online.aspx. Accessed 11 Dec 2014.
70. Hollowell JG, Staehling NW, Hannon WH, Flanders DW, Gunter EW, Maberly GF, et al. Iodine nutrition in the United States. Trends and public health implications: Iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab. 1998;83:3401-8.
71. Pan Y, Caldwell KL, Li Y, Caudill SP, Mortensen ME, Makhmudov A, et al. Smoothed urinary iodine percentiles for the US population and pregnant women: National Health and Nutrition examination survey, 2001-2010. Eur Thyroid J. 2013;2:127-34.
72. Lubitz CC, Kong CY, McMahon PM, Daniels GH, Chen YF, Economopoulos KP, et al. Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer. 2014;120:1345-52.
73. Pettersson B, Coleman MP, Ron E, Adami HO. Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer. 1996;65:13-9.
74. Rasmussen LB, Jorgensen T, Perrild H, Knudsen N, Krejbjerg A, Laurberg P, et al. Mandatory iodine fortification of bread and salt increases iodine excretion in adults in Denmark - a 11-year follow-up study. Clin Nutr. 2014;33:1033-40.
75. Blomberg M, Feldt-Rasmussen U, Andersen KK, Kjaer SK. Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation. Int J Cancer. 2012;131:2360-6.
76. Knudsen N, Bulow I, Jorgensen T, Laurberg P, Ovesen L, Perrild H. Goitre prevalence and thyroid abnormalities at ultrasonography: a comparative epidemiological study in two regions with slightly different iodine status. Clin Endocrinol (Oxf). 2000;53:479-85.
77. Sehestedt T, Knudsen N, Perrild H, Johansen C. Iodine intake and incidence of thyroid cancer in Denmark. Clin Endocrinol (Oxf). 2006;65:229-33.
78. Netea-Maier RT, Aben KKH, Casparie MK, den Heijer M, Grefte JMM, Slootweg P, et al. Trends in incidence and mortality of thyroid carcinoma in The Netherlands between 1989 and 2003: correlation with thyroid fine-needle aspiration cytology and thyroid surgery. Int J Cancer. 2008;123:1681-4.
79. Williams ED, Doniach I, Bjarnason O, Michie W. Thyroid Cancer in an Iodide Rich Area - Histopathological Study. Cancer. 1977;39:215-22.
80. Radespiel-Troger M, Batzler WU, Holleczek B, Luttmann S, Pritzkuleit R, Stabenow R, et al. Im Namen der Gesellschaft der epidemiologischen Krebsregister in Deutschland e V [Rising incidence of papillary thyroid carcinoma in Germany]. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2014;57:84-92.
81. Lise M, Franceschi S, Buzzoni C, Zambon P, Falcini F, Crocetti E, et al. Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis. Thyroid. 2012;22:27-34.
82. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med. 1992;93:363-9.
83. Ilias I, Alevizaki M, Lakka-Papadodima E, Koutras DA. Differentiated thyroid cancer in Greece: 1963-2000. Relation to demographic and environmental factors. Hormones (Athens). 2002;1:174-8.
84. Rego-Iraeta A, Perez-Mendez LF, Mantinan B, Garcia-Mayor RV. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid. 2009;19:333-40.
85. Wang Y, Wang W. Increasing Incidence of Thyroid Cancer in Shanghai, China, 1983-2007. Asia Pac J Public Health. 2015;27:NP223-9.
86. Dong W, Zhang H, Zhang P, Li X, He L, Wang Z, et al. The changing incidence of thyroid carcinoma in Shenyang, China before and after universal salt iodization. Med Sci Monit. 2013;19:49-53.
87. Teng WP, Shan ZY, Teng XC, Guan HX, Li YH, Teng D, et al. Effect of iodine intake on thyroid diseases in China. New Eng J Med. 2006;354:2783-93.
88. Zhu W, Liu X, Hu X, Zhou S, Wang Y, Zhang Y. Investigation on the iodine nutritional status and the prevalence of thyroid carcinoma in Zhoushan Archipelago residents. Wei Sheng Yan Jiu. 2012;41:79-82.
89. Chen ZX, Xu WM, Huang YM, Jin X, Deng J, Zhu SJ, et al. Associations of noniodized salt and thyroid nodule among the Chinese population: a large cross-sectional study. Am J Clin Nutr. 2013;98:684-92.
90. Wong EY, Ray R, Gao DL, Wernli KJ, Li W, Fitzgibbons ED, et al. Reproductive history, occupational exposures, and thyroid cancer risk among women textile workers in Shanghai, China. Int Arch Occ Env Hea. 2006;79:251-8.
91. Yin JH, Wang CC, Shao Q, Qu DH, Song ZY, Shan PF, Zhang T, Xu J, Liang Q, Zhang SZ, Huang J. Relationship between the Prevalence of Thyroid Nodules and Metabolic Syndrome in the Iodine-Adequate Area of Hangzhou, China: A Cross-Sectional and Cohort Study. Int J Endocrinol. 2014.
92. Burgess JR, Dwyer T, McArdle K, Tucker P, Shugg D. The changing incidence and spectrum of thyroid carcinoma in Tasmania (1978-1998) during a transition from iodine sufficiency to iodine deficiency. J Clin Endocrinol Metab. 2000;85:1513-7.
93. Burgess JR. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997). Thyroid. 2002;12:141-9.
94. Li M, Eastman CJ, Waite KV, Ma G, Zacharin MR, Topliss DJ, et al. Are Australian children iodine deficient? Results of the Australian National Iodine Nutrition Study. Med J Aust. 2006;184:165-9.
95. Harach HR, Ceballos GA. Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina Model. Endocr Pathol. 2008;19:209-20.
96. Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol. 2008;33:341-57.
97. Besic N, Hocevar M, Zgajnar J. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid. 2010;20:623-6.
98. Bacher-Stier C, Riccabona G, Totsch M, Kemmler G, Oberaigner W, Moncayo R. Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Thyroid. 1997;7:733-41.
99. Farahati J, Geling M, Mader U, Mortl M, Luster M, Muller JG, et al. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995. Thyroid. 2004;14:141-7.
100. Ceresini G, Corcione L, Michiara M, Sgargi P, Teresi G, Gilli A, et al. Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of Northern Italy, 1998 to 2009. Cancer. 2012;118:5473-80.
101. Guberan E. [Mortality trends in Switzerland. 3. Tumors: 1921-1978]. Schweiz Med Wochenschr Suppl. 1980;Suppl 11:1-18.
102. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf). 2005;62:156-62.
103. Harach HR, Galindez M, Campero M, Ceballos GA. Undifferentiated (Anaplastic) Thyroid Carcinoma and Iodine Intake in Salta, Argentina. Endocr Pathol. 2013;24:125-31.
104. Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. Am J Clin Pathol. 1985;83:135-58.
105. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol. 2010;22:486-97.
106. World Health Organization Statistical Information System (WHOSIS). WHO Mortality Database. Geneva: World Health Organization. Available at: http://apps.who.int/healthinfo/statistics/mortality/whodpms/.
107. WHO Vitamin and Mineral Nutrition Information System (VMNIS). Database on Iodine Deficiency. Available at: http://www.who.int/vmnis/database/iodine/en/. Accessed 11 Dec 2014.
108. Fukunaga FH, Yatani R. Geographic pathology of occult thyroid carcinomas. Cancer. 1975;36:1095-9.
109. Kovacs GL, Gonda G, Vadasz G, Ludmany E, Uhrin K, Gorombey Z, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid. 2005;15:152-7.
110. Neuhold N, Kaiser H, Kaserer K. Latent carcinoma of the thyroid in Austria: a systematic autopsy study. Endocr Pathol. 2001;12:23-31.
111. Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid - a study of 408 autopsy cases. Cancer. 1990;65:1173-9.
112. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid - a normal finding in Finland - a systematic autopsy study. Cancer. 1985;56:531-8.
113. Derwahl M, Studer H. Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp Clin Endocr Diab. 2001;109:250-60.
114. Krohn K, Fuhrer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev. 2005;26:504-24.
115. Horn-Ross PL, Morris JS, Lee M, West DW, Whittemore AS, McDougall IR, et al. Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev. 2001;10:979-85.
116. Memon A, Varghese A, Suresh A. Benign thyroid disease and dietary factors in thyroid cancer: a case-control study in Kuwait. Br J Cancer. 2002;86:1745-50.
117. Iribarren C, Haselkorn T, Tekawa IS, Friedman GD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer. 2001;93:745-50.
118. Pendergrast WJ, Milmore BK, Marcus SC. Thyroid cancer and thyrotoxicosis in the United States: their relation to endemic goiter. J Chronic Dis. 1961;13:22-38.
119. Clements FW. The relationship of thyrotoxicosis and carcinoma of the thyroid to endemic goitre. Med J Aust. 1954;2:894-7.
120. Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta-analysis. Thyroid. 2013;23:449-55.
121. Kolonel LN, Hankin JH, Wilkens LR, Fukunaga FH, Hinds MW. An epidemiologic study of thyroid cancer in Hawaii. Cancer Causes Control. 1990;1:223-34.
122. Truong T, Baron-Dubourdieu D, Rougier Y, Guenel P. Role of dietary iodine and cruciferous vegetables in thyroid cancer: a countrywide case-control study in New Caledonia. Cancer Causes Control. 2010;21:1183-92.
123. Clero E, Doyon F, Chungue V, Rachedi F, Boissin JL, Sebbag J, et al. Dietary iodine and thyroid cancer risk in French Polynesia: a case-control study. Thyroid. 2012;22:422-9.
124. Panityakul T, Bumrungsup C, Knapp G. On estimating residual heterogeneity in random-effects meta-regression: a comparative study. J Stat Theory Appl. 2013;12:253-65.
125. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org/. 2014.
126. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1-48.
127. Lumley T. rmeta: Meta-analysis. R package version 2.16. Available at: http://CRAN.R-project.org/package=rmeta. 2012.
128. Liu ZT, Lin AH. Dietary factors and thyroid cancer risk: a meta-analysis of observational studies. Nutr Cancer. 2014;66:1165-78.
129. Bosetti C, Kolonel L, Negri E, Ron E, Franceschi S, Dal Maso L, et al. A pooled analysis of case-control studies of thyroid cancer. VI. Fish and shellfish consumption. Cancer Causes Control. 2001;12:375-82.
130. Perrine CG, Sullivan KM, Flores R, Caldwell KL, Grummer-Strawn LM. Intakes of dairy products and dietary supplements are positively associated with iodine status among US Children. J Nutr. 2013;143:1155-60.
131. Zimmermann MB. Symposium on 'Geographical and geological influences on nutrition': Iodine deficiency in industrialised countries. Proc Nutr Soc. 2010;69:133-43.
132. Haldimann M, Alt A, Blanc A, Blondeau K. Iodine content of food groups. J Food Compos Anal. 2005;18:461-71.
133. Brauer VF, Brauer WH, Fuhrer D, Paschke R. Iodine nutrition, nodular thyroid disease, and urinary iodine excretion in a German university study population. Thyroid. 2005;15:364-70.
134. Galanti MR, Hansson L, Bergstrom R, Wolk A, Hjartaker A, Lund E, et al. Diet and the risk of papillary and follicular thyroid carcinoma: a population-based case-control study in Sweden and Norway. Cancer Causes Control. 1997;8:205-14.
135. Franceschi S, Levi F, Negri E, Fassina A, La Vecchia C. Diet and thyroid cancer: a pooled analysis of four European case-control studies. Int J Cancer. 1991;48:395-8.
136. Mack WJ, Preston-Martin S, Dal Maso L, Galanti R, Xiang M, Franceschi S, et al. A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes Control. 2003;14:773-85.
137. Bandurska-Stankiewicz E, Aksamit-Bialoszewska E, Rutkowska J, Stankiewicz A, Shafie D. The effect of nutritional habits and addictions on the incidence of thyroid carcinoma in the Olsztyn province of Poland. Endokrynol Pol. 2011;62:145-50.
138. Park Y, Leitzmann MF, Subar AF, Hollenbeck A, Schatzkin A. Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study. Arch Intern Med. 2009;169:391-401.
139. Schneider AB, Shore-Freedman E, Weinstein RA. Radiation-induced thyroid and other head and neck tumors: occurrence of multiple tumors and analysis of risk factors. J Clin Endocrinol Metab. 1986;63:107-12.
140. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141:259-77.
141. Williams D. Twenty years' experience with post-Chernobyl thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:1061-73.
142. Robbins J, Dunn JT, Bouville A, Kravchenko VI, Lubin J, Petrenko S, et al. Iodine nutrition and the risk from radioactive iodine: a workshop report in the chernobyl long-term follow-up study. Thyroid. 2001;11:487-91.
143. Shakhtarin VV, Tsyb AF, Stepanenko VF, Orlov MY, Kopecky KJ, Davis S. Iodine deficiency, radiation dose, and the risk of thyroid cancer among children and adolescents in the Bryansk region of Russia following the Chernobyl power station accident. Int J Epidemiol. 2003;32:584-91.
144. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst. 2005;97:724-32.
145. Tronko MD, Howe GR, Bogdanova TI, Bouville AC, Epstein OV, Brill AB, et al. A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: Thyroid cancer in Ukraine detected during first screening. J Natl Cancer I. 2006;98:897-903.
146. Zablotska LB, Ron E, Rozhko AV, Hatch M, Polyanskaya ON, Brenner AV, et al. Thyroid cancer risk in Belarus among children and adolescents exposed to radioiodine after the Chornobyl accident. Br J Cancer. 2011;104:181-7.
147. Hatch M, Polyanskaya O, McConnell R, Gong ZH, Drozdovitch V, Rozhko A, et al. Urinary Iodine and goiter prevalence in Belarus: experience of the Belarus-American cohort study of thyroid cancer and other thyroid diseases following the Chornobyl nuclear accident. Thyroid. 2011;21:429-37.
148. Heitz P, Moser H, Staub JJ. Thyroid cancer: a study of 573 thyroid tumors and 161 autopsy cases observed over a thirty-year period. Cancer. 1976;37:2329-37.
149. Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P, Gomez I. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid. 1998;8:1179-83.
150. Huszno B, Szybinski Z, Przybylik-Mazurek E, Stachura J, Trofimiuk M, Buziak-Bereza M, et al. Influence of iodine deficiency and iodine prophylaxis on thyroid cancer histotypes and incidence in endemic goiter area. J Endocrinol Invest. 2003;26:71-6.
151. Pingitore R. Rilievi morfologici autoptici su 111 tiroidi clinicamente normali in un'area italiana senza edemia gozzigena. Pathologica. 1982;74:545-52.
152. Arellano L, Ibarra A. Occult carcinoma of the thyroid gland. Pathol Res Pract. 1984;179:88-91.
153. Sobrinho-Simoes MA, Sambade MC, Goncalves V. Latent thyroid-carcinoma at autopsy - study from Oporto, Portugal. Cancer. 1979;43:1702-6.
154. Siegal A, Modan M. Latent Carcinoma of Thyroid in Israel - a Study of 260 Autopsies. Israel J Med Sci. 1981;17:249-53.
155. Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol. 1988;90:72-6.
156. Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022-9.
157. Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology. 1993;23:319-25.
158. Avetisian IL, Petrova GV. Latent thyroid pathology in residents of Kiev, Ukraine. J Environ Pathol Toxicol Oncol. 1996;15:239-43.
159. Solares CA, Penalonzo MA, Xu M, Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolaryng. 2005;26:87-90.
160. Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmo, Sweden. Cancer. 1981;47:319-23.
161. Komorowski RA, Hanson GA. Occult thyroid pathology in the young-adult - an autopsy study of 138 patients without clinical thyroid-disease. Hum Pathol. 1988;19:689-96.
162. Bisi H, Fernandes VS, de Camargo RY, Koch L, Abdo AH, de Brito T. The prevalence of unsuspected thyroid pathology in 300 sequential autopsies, with special reference to the incidental carcinoma. Cancer. 1989;64:1888-93.
163. Ottino A, Pianzola HM, Castelletto RH. Occult papillary thyroid-carcinoma at autopsy in La-Plata, Argentina. Cancer. 1989;64:547-51.
164. Thorvaldsson SE, Tulinius H, Bjornsson J, Bjarnason O. Latent thyroid-carcinoma in Iceland at autopsy. Pathol Res Pract. 1992;188:747-50.
165. Chong PY. Thyroid carcinomas in Singapore autopsies. Pathology. 1994;26:20-2.
166. Mitselou A, Vougiouklakis T, Peschos D, Dallas P, Agnantis NJ. Occult thyroid carcinoma. A study of 160 autopsy cases. The first report for the region of Epirus-Greece. Anticancer Res. 2002;22:427-32.
167. Tanriover O, Comunoglu N, Eren B, Comunoglu C, Turkmen N, Dogan M, et al. Occult papillary thyroid carcinoma: prevalence at autopsy in Turkish people. Eur J Cancer Prev. 2011;20:308-12.
168. Hazard JB, Kaufman N. A survey of thyroid glands obtained at autopsy in a so-called goiter area. Am J Clin Pathol. 1952;22:860-5.
169. Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab. 1955;15:1270-80.
170. Hull OH. Critical analysis of two hundred twenty-one thyroid glands; study of thyroid glands obtained at necropsy in Colorado. AMA Arch Pathol. 1955;59:291-311.
171. Brierre Jr JT, Dickson LG. Clinically unsuspected thyroid disease. GP. 1964;30:94-8.
172. Silverberg SG, Vidone RA. Carcinoma of thyroid in surgical and postmortem material - analysis of 300 cases at autopsy and literature review. Ann Surg. 1966;164:291-9.
173. Farooki MA. Epidemiology and pathology of cancer of the thyroid. I. Material, methods and results. Int Surg. 1969;51:232-43.
174. Sampson RJ, Woolner LB, Bahn RC, Kurland LT. Occult thyroid carcinoma in Olmsted County, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer. 1974;34:2072-6.
175. de Matos PS, Ferreira AP, Ward LS. Prevalence of papillary microcarcinoma of the thyroid in Brazilian autopsy and surgical series. Endocr Pathol. 2006;17:165-73.
176. Fukunaga FH, Lockett LJ. Thyroid carcinoma in the Japanese in Hawaii. Arch Pathol. 1971;92:6-13.